Citius Oncology reports sustained quality-of-life gains in LYMPHIR trial responders
Bitget2026/11/04 22:45- Citius Oncology reported sustained improvements in skin-related quality of life among LYMPHIR responders with relapsed or refractory cutaneous T-cell lymphoma.
- Results from pivotal Study 302 were presented at the EORTC-CLTG annual meeting in Berlin, held October 8-10, 2026.
- Responders also reported improved overall quality of life; some heavily pretreated patients experienced sustained relief from itching.
- Quality-of-life findings were exploratory. The trial was not designed to evaluate these outcomes, and no formal statistical comparisons were performed.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
British Pound hits session highs at 1.3420 amid broadbased US Dollar weakness
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Crypto prices
More
